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ABSTRACT 
 
Selective autophagy underlies many of the important physiological roles that autophagy 
plays in multicellular organisms, but the mechanisms involved in cargo selection are 
poorly understood. Here we describe a molecular mechanism that can target 
conventional endosomes for autophagic degradation. We show that the human 
transmembrane protein TMEM59 contains a minimal 19-aminoacid peptide in its 
intracellular domain that promotes LC3 labeling and lysosomal targeting of its own 
endosomal compartment. Interestingly, this peptide defines a novel protein motif that 
mediates interaction with the WD-repeat domain of ATG16L1, thus providing a 
mechanistic basis for the activity. The motif is represented with the same ATG16L1-
binding ability in other molecules, suggesting a more general relevance. We propose 
that this motif may play an important role in targeting specific membranous 
compartments for autophagic degradation, and therefore it may facilitate the search for 
adaptor proteins that promote selective autophagy by engaging ATG16L1. Endogenous 
TMEM59 interacts with ATG16L1 and mediates autophagy in response to 
Staphylococcus aureus infection. 
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INTRODUCTION 
 
Macroautophagy (hereafter referred to as autophagy) is a catabolic process that 
promotes degradation of bulk cytoplasmic constituents and recycles the resulting basic 
components as metabolic precursors (Mizushima, 2007; Yang and Klionsky, 2009). 
This phenomenon involves sequestration of the doomed material into double-membrane 
vesicles (autophagosomes) that eventually fuse with lysosomes for degradation of their 
contents (Rubinsztein et al., 2012). Although the autophagic process digests random 
cytoplasm to maintain nutrient supply during stressful situations (Rabinowitz and 
White, 2010; Singh and Cuervo, 2011), it can also target specific, superfluous or 
potentially harmful components, a less characterized phenomenon called selective 
autophagy (Komatsu and Ichimura, 2010; Kroemer et al., 2010; Mizushima and 
Komatsu, 2011). 
The autophagic pathway is highly conserved in all eukaryotic organisms 
(Mizushima et al., 2011; Nakatogawa et al., 2009). In mammalian cells, two protein 
complexes (ULK1/ATG1-mTOR-ATG13-FIP200 and ClassIII Pi3K-BECLIN/ATG6-
ATG14) act coordinately to initiate autophagosome nucleation (He and Klionsky, 
2009). Membrane elongation and autophagosome closure are driven by two ubiquitin-
like modification systems that converge in the lipidation of processed LC3/ATG8 
(LC3I) to produce a membrane-bound form called LC3II (Noda et al., 2009; Yang and 
Klionsky, 2009). ATG12 and LC3 are ubiquitin-like modifiers, and ATG7 is the E1 
enzyme for both molecules. In an E2-like step, ATG10 promotes the bonding of ATG12 
to ATG5, and ATG3 binds LC3. ATG5-ATG12 then interacts with ATG16L1 to 
assemble a final E3 system for the conjugation of phosphatidylethanolamine (PE) to 
LC3I (Tanida et al, 2011). In this complex, ATG5-ATG12 holds the E3-ligase activity 
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(Hanada et al., 2007), whereas ATG16L1 determines the site of LC3 lipidation (Fujita 
et al., 2008). Thus, ATG16L1 recruits ATG12-ATG5 to defined membrane 
localizations, and brings LC3 close to a membranous PE source through interaction 
between ATG12 and ATG3-LC3I (Fujita et al., 2008). LC3 lipidation and its 
association with autophagosomes are widely used as autophagic reporter systems 
(Mizushima et al., 2010). 
Autophagy has important implications in processes like tumor suppression, 
neurodegeneration or native immunity (Cecconi and Levine, 2008; Levine and 
Kroemer, 2008; Levine et al., 2011), and selective autophagy plays a role in these 
activities (Mizushima and Komatsu, 2011; Mizushima et al., 2008). For example, tumor 
suppression might result from a specific elimination of damaged organelles that produce 
pro-inflammatory and DNA-damaging reactive oxygen species (Dikic et al., 2010; 
Mathew et al., 2009; Mathew and White, 2011). Atg deletion in the central nervous 
system (Hara et al., 2006; Komatsu et al., 2006) causes neurodegeneration through 
accumulation of insoluble protein aggregates (Komatsu et al., 2007), revealing a critical 
housekeeping role of autophagy in clearing toxic garbage (Garcia-Arencibia et al., 
2010; Mizushima and Komatsu, 2011). Elimination of foreign invaders involves their 
recognition by the autophagic machinery, whether they are loose in the cytoplasm 
(Deretic, 2011; Deretic and Levine, 2009; Shahnazari and Brumell, 2011) or enclosed in 
phagosomes (Gutierrez et al., 2004; Sanjuan et al., 2007). 
Although the mechanisms that provide cargo specificity in selective autophagy 
remain poorly understood, some examples are available. Damaged mitochondria (Youle 
and Narendra, 2011), insoluble protein precipitates (Knaevelsrud and Simonsen, 2010) 
or cytosolic bacteria (Fujita and Yoshimori, 2011; Randow, 2011) first become 
ubiquitinated, and adaptor proteins that simultaneously bind ubiquitin and LC3 target 
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them for autophagic degradation (Johansen and Lamark, 2011; Kirkin et al., 2009b). 
p62 (Pankiv et al., 2007), NBR1 (Kirkin et al., 2009a), NDP52 (Thurston et al., 2009) 
and Optineurin (Wild et al., 2011) are some of these adaptors. Depolarized 
mitochondria are also subjected to autophagy by recruiting NIX/bNIP3L, another LC3-
binding protein (Novak et al., 2010). Interestingly, all these linker proteins share a 
common LC3-interacting motif (Noda et al., 2010). In an additional example, 
phagosomes containing activated TLR2 recruit BECLIN/ATG6 to promote LC3 
labeling of this otherwise non-autophagic compartment (Sanjuan et al., 2007). NOD 
proteins recognize bacteria at the entry site and bind ATG16L1 to cause LC3 activation 
(Travassos et al., 2010). Thus, a variety of proteins function as adaptor modules that 
couple the selected substrates directly with the autophagic machinery to promote LC3 
decoration of the targeted item. Given the breadth of processes where selective 
autophagy is involved, one could anticipate the existence of additional linker families 
that, similar to ubiquitin/LC3 adaptors, might engage specific autophagic effectors 
through common protein signatures. 
Here we show that the human transmembrane molecule TMEM59 defines a 
novel ATG16L1-binding motif through which the protein promotes labeling of its own 
endocytic compartment with LC3, in a process that links conventional endocytosis to 
autophagic degradation. Interestingly, the motif is present with a similar ATG16L1-
binding activity in other molecules. 
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RESULTS  
 
TMEM59 induces LC3 activation 
During an extended screening to identify cDNAs whose expression causes cell death 
(Alcalá et al., 2008), we found clone P15 as able to induce a morphologically atypical 
death modality (not shown). P15 encoded TMEM59 (Supplementary Figure S1A), a 
predicted type-I transmembrane protein (C terminus intracellular), known to regulate 
glycosylation of the amyloid precursor protein (APP) (Ullrich et al., 2010). 
Unconventional death morphologies have been linked to autophagic (type II) cell death 
(Shimizu et al., 2004), so to explore a possible pro-autophagic property of TMEM59 we 
confronted this molecule with reporter systems based on ATG8/LC3 (Mizushima et al., 
2010). TMEM59 expression induced HA-LC3 lipidation (Figure 1A and C) and GFP-
LC3 redistribution to vesicular structures (Figure 1B, D and E), thus confirming its pro-
autophagic capacity. Although functional divergence between different LC3-family 
members may exist (Chen and Klionsky, 2011), TMEM59 activated the LC3A and B 
isoforms comparably (see Figures 1C, D and E). 
 
Characterization of endogenous TMEM59 
Northern-blot assays revealed two TMEM59-specific mRNAs present in most cell types 
(Supplementary Figure S1B). Antibodies against the putative extracellular domain (N 
terminus) recognized a 34-36 kD band (Supplementary Figure S1C and D) whose 
diffuse nature is likely due to glycosylation (Supplementary Figure S1E). TMEM59 
localized to small cytoplasmic vesicles that were difficult to detect in 
immunolocalization studies (Supplementary Figure S2A), although the ectopic protein 
was easily observed (Supplementary Figure S2B). These results suggested low basal 
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levels, perhaps as a consequence of active degradation. Consistently, inhibition of 
protein synthesis rapidly reduced TMEM59 expression (Supplementary Figure S2C), 
and lysosome inhibitors induced the protein without altering its mRNA levels 
(Supplementary Figure S2D, E and F). Therefore, the low basal expression of TMEM59 
is probably due to intense lysosomal degradation. This constitutive degradation is not 
autophagic, because neither defective autophagy (Supplementary Figure S2G) nor 
increased autophagic turnover (Supplementary Figure S2H) altered TMEM59 
expression levels. 
The TMEM59-positive vesicles strongly colocalized with LAMP2 and CD63, 
and partially with EEA1 (Supplementary Figure S3A and B), suggesting a main 
localization in late endosomes/lysosomes and a transient presence in early endosomes. 
Although previous studies with a different antibody (against the C terminus) showed 
Golgi localization (Ullrich et al., 2010), we found no colocalization with Golgi markers 
(Supplementary Figure S3A and B). Intriguingly, transfected TMEM59 was expressed 
at the cell surface (Supplementary Figure S3C) but the endogenous molecule was not 
found in this location (Supplementary Figure S3D). Some lysosomal membrane 
proteins transit first through the plasma membrane (Janvier and Bonifacino, 2005; 
Saftig and Klumperman, 2009), an indirect route revealed by agents that promote their 
accumulation at the cell surface by inhibiting trafficking to the lysosome (chloroquine, 
for example) (Lippincott-Schwartz and Fambrough, 1987). Consistent with this 
possibility, chloroquine treatment provoked surface exposure of TMEM59 
(Supplementary Figure S3D, E and F). Bafilomycin caused the same effect, although 
less efficiently (not shown). Importantly, as all these staining procedures were done on 
unpermeabilized cells and the antibody recognizes the N-terminal part of the molecule, 
these results confirm a type I topology. 
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Therefore, TMEM59 is a glycosylated, type I transmembrane protein that mainly 
localizes to late endosomes/lysosomes. The protein is probably first exported to the cell 
surface and then actively endocytosed to transiently localize in early endosomes on its 
way to the late endosomal/lysosomal compartment. In this final destination, TMEM59 
becomes quickly degraded, a phenomenon that results in low expression levels. 
Since TMEM59 has no sequence features that could provide mechanistic clues 
about its pro-autophagic activity, we reasoned that the characterization of this function 
might reveal undescribed mechanisms of autophagic regulation. 
 
TMEM59 induces autophagy through a minimal 19-aminoacid subdomain 
To dissect the autophagic activity of TMEM59 we first determined the signaling region. 
A deleted version of the molecule lacking the whole intracellular domain (ID) was 
unable to activate LC3 (Figure 2A, B and C), thus ascribing a necessary role to this part 
of the protein. To evaluate if this domain was also sufficient to induce autophagy, we 
placed it in a different molecular context that preserves the type I transmembrane 
configuration. Chimeric molecules containing the extracellular part of CD16 and the 
transmembrane region of CD7 (CD16:7) fulfill this requirement, and have been used 
before in functional assays since they can be stimulated by aggregation with anti-CD16 
antibodies (Kolanus et al., 1993). Aggregation of the CD16:7 chimera fused to the ID of 
TMEM59 caused HA-LC3 conversion (Figure 2D, E and F) and GFP-LC3 
redistribution to a perinuclear vesicle cluster (Figure 2G and H). These results indicate 
that the cytoplasmic region of TMEM59 suffices for autophagy induction, and suggest 
that an aggregation event can unleash the activity. 
Serial C-terminal deletions of TMEM59 were tested by overexpression to further 
map the active subdomain. These experiments showed that aminoacids 263-281 are 
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necessary for the activity, because deletions beyond Δ282 were no longer functional 
(Figure 3A and B). When evaluated in the context of the CD16:7 chimera, this 
subdomain proved sufficient to activate LC3 (Figure 3C, D and F). In fact, this 19-
aminoacid stretch retained the full potential of the whole ID to stimulate autophagy 
when both constructs were evaluated in parallel (Figure 3C, D and F). In contrast, the 
remaining ID (282-323) was inactive (Figure 3E and F). Therefore, a minimal 19-
aminoacid subdomain between aminoacids 263-281 (Figure 3G) holds the autophagic 
potential of the molecule. 
 
The active subdomain induces LC3 labeling of its own vesicular compartment 
To explore the nature of the autophagic response induced by this minimal peptide we 
first tested its function in cells depleted of the essential mediators ATG5 or ATG7. 
Reduced levels of these effectors decreased the autophagic potential of CD16:7 
constructs containing the minimal active fragment (CD16:7-263-281; Supplementary 
Figure S4A, B and C), indicating that the activity proceeds through an ATG5/ATG7-
dependent route. 
We next determined the subcellular distribution of the autophagic process. 
Unexpectedly, both overexpressed TMEM59 and aggregated, endocytosed CD16:7-
263-281 chimeras tightly colocalized with activated GFP-LC3 (Supplementary Figure 
S5A and B). Again, 293 cells displayed a clustered signal (see Supplementary Figure 
S5B), but when the chimera experiment was repeated in JAR cells we detected 
individual vacuoles stained for both markers (Figure 4A). Most chimera-positive 
vesicles were labeled with GFP-LC3 in these cells (Supplementary Figure S5C), and 
GFP-LC3 appeared to stain the vesicle periphery (see inset Figure 4A). These vacuoles 
colocalized with EEA1 and/or CD63 (Figure 4B), suggesting that, once aggregated, the 
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construct follows the regular endocytic route to the lysosome. In addition, electron 
microscopy studies showed that the LC3-labeled vesicles containing endocytosed 
chimera presented single membranes (Figure 4C), and so did the vacuoles induced by 
straight TMEM59 overexpression (Supplementary Figure S5D). These data point to the 
notion that single-membrane endosomes become decorated with LC3 in what appears to 
be an atypical autophagic event not involving canonical double-membrane 
autophagosomes. Consistent with this idea, TMEM59 does not seem to influence 
conventional autophagy. For instance, neither aggregation of the active chimera nor 
TMEM59 overexpression altered the expression levels of three recognized autophagic 
substrates: p62, NBR1 or GFP-huntingtin-Q74 (Mizushima et al., 2010) 
(Supplementary Figure S6). Similarly, TMEM59 depletion did not impact on the way 
the levels of these substrates (or LC3II) were changed by standard modulators of 
autophagy (bafilomycin or starvation, Supplementary Figures S7 and S8). Therefore, 
the autophagic activity of TMEM59 seems unrelated to canonical autophagy, and 
involves LC3 labeling of the same single membrane endosomes where the molecule 
becomes activated.  
An important question in the field is whether an observed accumulation of active 
LC3 reflects a real increase in LC3 lipidation and autophagic flux, or it simply 
represents arrest of autophagosomal degradation (Klionsky et al., 2008; Mizushima and 
Yoshimori, 2007; Mizushima et al., 2010). To discern between both possibilities, we 
conducted aggregation studies in the absence or presence of a lysosomal inhibitor 
(bafilomycin). The presence of this drug increased the levels of LC3II generated by the 
active CD16:7 construct (CD16:7-263-281; Figure 4D), suggesting that the minimal 
peptide adds LC3II beyond the degradation blockade imposed by the inhibitor. In 
addition, the fact that TMEM59 does not promote accumulation of autophagic 
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substrates (see Supplementary Figure S6), argues against the idea that the subdomain 
blocks autophagic degradation. Taken together, these data suggest that the active 
subdomain of TMEM59 mainly functions by promoting LC3II synthesis. Since virtually 
all activated GFP-LC3 colocalized with the endocytosed chimera (see Figure 4A and 
Supplementary Figure S5B), we interiorized the notion that this synthesis is induced in 
situ by the aggregation event. 
We next examined whether LC3 labeling targets the marked vesicles for 
degradation. Anti-CD16 Western-blots showed that the stimulated CD16:7-263-281 
chimera produced a lower molecular weight smear indicative of protein destruction 
(Figure 4E). This decay was reduced by E64d and pepstatin (Supplementary Figure S9), 
implying lysosomal involvement and suggesting again that the active subdomain does 
not obstruct vesicle maturation. Importantly, the degradation was inhibited by ATG5 
depletion (Figure 4F), arguing that it is promoted by the autophagic activity triggered in 
response to aggregation. Consequently, the active subdomain of TMEM59, if 
stimulated, suffices to direct its own endocytic compartment for autophagic 
degradation. 
 
The active subdomain defines a novel ATG16L1-binding motif 
We hypothesized that the active peptide might conceal an underlying protein motif that 
retains function. To test this idea, we performed an alanine scanning study where all 
residues were individually mutated to alanine and the resulting derivatives were 
functionally tested using the CD16:7 chimera. All constructs exhibited comparable cell 
surface expression levels (Supplementary Figure S10A), and therefore were equally 
available for aggregation. Four mutants (Y268A, E272A, Y277A and L280A) showed 
reduced capacity to lipidate HA-LC3 (Figure 5A), and only three (Y268A, Y277A and 
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L280A) had a diminished potential to promote GFP-LC3 redistribution or colocalization 
with the endocytosed chimera (Figures 5B and C). Interestingly, E272A activated GFP-
LC3 normally (Figures 5B and C). Given that this mutant was inactive in HA-LC3 
conversion (see Figure 5A), this result suggests that the colocalizing GFP-LC3 pool is 
not lipidated. Thus, recruitment of LC3I and its conversion to LC3II might be 
dissociable events, and E272 would only be involved in the latter activity. Whatever the 
mechanistic implications of this finding may be, these results show that Y268, E272, 
Y277 and L280, arranged in a pattern defined by TMEM59 (Y-X3-E-X4-Y-X2-L), are 
required for in situ LC3II generation in this context. Consistent with their individual 
importance, mutation of the four critical residues at once (4M versions) prevented LC3 
activation by chimera aggregation (Figure 5D, E and F) or TMEM59 overexpression 
(Supplementary Figure S10B and C). Although the 4M chimera showed slightly higher 
surface expression and less endocytosis upon aggregation (Supplementary Figure S10D 
and E), these partial defects are unlikely to explain the complete signaling blockade 
observed (see Figure 5D, E and F). In addition, the signaling impairment was not 
caused by a major mislocalization of the 4M mutant (Supplementary Figure S10F). 
Additional studies showed that Y268 can be mutated to W (but not F) without 
functional loss. Similarly, E272 can be substituted by D, and Y277 by W or F. 
However, L280 mutation to V depressed the activity (Supplementary Figure S11A and 
B). These data show that the motif can accommodate some flexibility, and point to the 
following final formulation: [YW]-X3-[ED]-X4-[YWF]-X2-L. 
The notion that the active subdomain promotes in situ LC3II synthesis suggests 
local engagement of the autophagic machinery. Colocalization studies revealed frequent 
apposition events between the aggregated, endocytosed CD16:7-263-281 chimera and 
GFP-ATG16L1 (Figure 6A), whereas GFP-BECLIN (Figure 6A) or other GFP-ATG 
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constructs (not shown) were negative. GFP-ATG5 only associated clearly with the 
internalized chimera when untagged ATG16L1 was also present (Supplementary Figure 
S12). Therefore, ATG16L1 is recruited at the site where the stimulated chimera is 
located, and probably brings ATG5 along with it. To explore if the active subdomain 
can actually bind ATG16L1, we performed coimmunoprecipitation assays. 
Consistently, both full-length TMEM59 and its largest active deletion (Δ282, see Figure 
3A and B) coprecipitated with ATG16L1 (Figure 6B and C). This interaction was 
decreased in the case of the 4M derivatives (Figure 6B and C), arguing that it is 
mediated by the identified motif. Interestingly, the 263-281 peptide fused to GST 
sufficed to precipitate ATG16L1 and, again, the mutated version was inactive (Figure 
6D). This result indicates that the interaction does not require membrane localization of 
the TMEM59 partner, and opens the possibility to evaluate direct binding in pull-down 
assays with proteins expressed in bacteria. A purified GST-263-281 fusion protein 
precipitated ATG16L1 from crude bacterial extracts, whereas the 4M version was inert 
(Figure 6E). Therefore, the minimal active subdomain of TMEM59 directly interacts 
with ATG16L1 through the identified protein motif. Consistent with a critical role of 
this mediator in the autophagic potential of TMEM59, ATG16L1 depletion reduced the 
ability of the CD16:7 chimera to activate LC3 (Supplementary Figure S13A and B). 
Mammalian ATG16L1 contains a C-terminal WD-repeat domain (WD domain) 
whose function is unclear. This domain is absent in the yeast ortholog (Mizushima et 
al., 2003) and is dispensable for conventional autophagy (Fujita et al., 2009), suggesting 
that it might be involved in specialized forms of autophagy. Coimmunoprecipitation 
studies showed that the WD domain is both necessary (Figures 7A and B) and sufficient 
(Figures 7C and D) for interaction with TMEM59 through the ATG16L1-binding motif 
(Figures 7E and F). 
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The novel ATG16L1-binding motif includes YXXL (277-280), a signature 
similar to YXXØ, involved in endocytosis and sorting of transmembrane proteins 
(Bonifacino and Traub, 2003). In fact, the 4M chimera showed less intracellular signal 
after aggregation (see Supplementary Figure S10E), suggesting reduced endocytosis. 
Consistent with a possible role of the motif in trafficking, wild-type TMEM59 
coprecipitated with the μ chains of the clathrin adaptors AP1 (AP1M1) and AP2 
(AP2M1), whereas the 4M version did not (Supplementary Figures S14A and B). Since 
both AP2 and clathrin are known to bind ATG16L1 (Ravikumar et al., 2010), this result 
raises the possibility that these sorting adaptors (or clathrin) might facilitate binding of 
the motif to ATG16L1. However, depletion of AP1M1, AP2M1 or the clathrin heavy 
chain (CHC), did not prevent interaction between TMEM59 and ATG16L1 
(Supplementary Figure S14C), thus arguing against this idea. In addition, a GST-263-
281 form where Y277 and L280 were mutated to alanine (2M) did not bind ATG16L1 
in a pull-down assay (Supplementary Figure S14D), indicating that, irrespective of its 
possible involvement in trafficking, the YXXL signature in TMEM59 does participate 
in direct ATG16L1 recognition. This pattern also resembles WXXL, implicated in LC3 
binding (Noda et al., 2010). However, LC3 did not bind the active subdomain in 
coimmunoprecipitation assays (not shown). 
 
The ATG16L1-binding motif is present in other molecules 
To evaluate if the identified motif exists in other proteins with a similar ATG16L1-
binding functionality, we searched the protein sequence bank using the Prosite 
algorithm and a version of the motif where the distances between aminoacids were 
flexibilized ([YW]-X(2,6)-[ED]-X(2,6)-[YWF]-X2-L). Interestingly, the pattern was found 
in molecules previously involved in selective autophagy. Thus, NOD proteins are 
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known to recruit ATG16L1 at the bacterial entry site (Travassos et al. 2010), and the N-
terminal CARD of NOD2 (NOD2-CARD1) includes the motif (Figure 8A). 
Surprisingly, the CARD present in its relative NOD1 (NOD1-CARD) lacks the pattern 
(Figure 8A). In addition, TLR2 promotes LC3 labeling of conventional phagosomes 
(Sanjuan et al., 2007), and the motif is present in its intracellular region (TLR2-ID; 
Figure 8B). Coimmunoprecipitation studies showed that NOD2-CARD1 and TLR2-ID 
were able to bind ATG16L1 (Figure 8C and D), whereas NOD1-CARD was inactive 
(Figure 8C). These interactions were again mediated by the WD domain of ATG16L1 
(Supplementary Figures S15A and B). Consistent with a role of the identified 
ATG16L1-binding pattern in these binding events, mutant versions of NOD2-CARD1 
and TLR2-ID lacking the motif lost the potential to coprecipitate with ATG16L1 
(Figure 8E). Two additional proteins not previously linked to autophagy (T3JAM and 
DEDD2) also presented the pattern (Figure 8F), and bound ATG16L1 through this 
region (Figure 8G and H). The minimal peptides harboring the motif in all these 
molecules conferred ATG16L1-binding potential to an inactive version of TMEM59 
(Supplementary Figure S16), indicating that they suffice to bind ATG16L1. Although 
establishing the precise functional consequences of these binding events requires 
additional studies, our results show that the identified ATG16L1-binding motif has a 
wider representation. 
 
Endogenous TMEM59 mediates autophagy during Staphylococcus aureus infection 
Taken together, our studies with the recombinant molecule suggest that endogenous 
TMEM59 might participate in promoting autophagic targeting of the membranous 
compartment where it becomes activated by aggregation. Autophagy directed to 
membrane-enclosed compartments occurs during some bacterial infections (Campoy 
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and Colombo, 2009; Deretic and Levine, 2009; Shahnazari and Brumell, 2011). For 
example, phagosomes containing Mycobacterium tuberculosis and Staphylococcus 
aureus undergo an autophagic process that, in the first case, helps fight infection 
(Gutierrez et al., 2004), and in the second case is required for bacterial replication 
(Schnaith et al., 2007). In fact, the initial export of endogenous TMEM59 to the plasma 
membrane and its subsequent trafficking through endosomes to the lysosome suggest a 
function along this route, a possibility that fits well with the phagosomal niche 
subjected to autophagy during bacterial invasion. Consistent with this view, depletion of 
TMEM59 blocked LC3II induction provoked by one of these bacteria (S. aureus, SA) at 
early infection times (Figure 9A; Supplementary Figures S17A and B). The pathway 
that generates LC3II at this stage has unconventional features, since it does not impact 
on the levels of conventional autophagic substrates (p62 or NBR1, see Figure 9A, 
Supplementary Figure S17C) and it does not rely on BECLIN-1 or VPS34 
(Supplementary Figure S17D). We also detected colocalization events between 
TMEM59, bacteria and Cherry-LC3 in what appeared to be bacterial sacs (Figure 9B) 
that were limited by single membranes (Supplementary Figure S17E). Intriguingly, 
TMEM59 expression was upregulated without mRNA contribution (Supplementary 
Figure S17F), suggesting that the protein becomes stabilized early during infection. 
Triple colocalization events between TMEM59, bacteria and Cherry-ATG16L1 were 
also found (Figure 9C), arguing that TMEM59 might recruit ATG16L1. In agreement 
with this idea, the number of TMEM59/ATG16L1 complexes increased in the presence 
of bacteria (Figure 9D). Taken together, these results point to a scenario where, in 
response to SA infection, TMEM59 becomes activated and promotes LC3 labeling of 
single-membrane bacterial phagosomes by directly engaging ATG16L1. This activity 
appears to have physiological consequences, since TMEM59 depletion resulted in 
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reduced bacterial recovery from infected cells (Figure 9E), a result consistent with the 
known requirement of autophagy for SA replication (Schnaith et al., 2007). These data 
confirm that endogenous TMEM59 can perform an in situ autophagic function whose 
mechanistic details resemble those established for the recombinant molecule. 
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DISCUSSION 
 
Selective autophagy underlies many of the important roles that autophagy plays in 
mammalian organisms, and therefore identification of the mechanisms that control this 
phenomenon and help define cargo selection becomes a relevant theme. Results 
presented here contribute to this general goal by identifying a novel protein motif that 
binds ATG16L1 and promotes an autophagic process directed to the endocytic 
compartment where the motif undergoes activation. 
We discovered this minimal signature by studying TMEM59, a protein initially 
found as an inducer of atypical death. In retrospect, it seems plausible that this death 
process resulted from excessive autophagy caused by overexpression of the molecule, 
since exaggerated autophagy can provoke cell death (Eisenberg-Lerner et al., 2009; 
Gozuacik and Kimchi, 2007). TMEM59 has been involved in the complex 
glycolsylation of APP (Ullrich et al., 2010), but how this phenomenon relates to the 
function described here is unknown. 
To characterize the active peptide in TMEM59 we used CD16:7 chimeric 
molecules. This artificial system preserves the native topology of the protein and 
provides an activation switch to test activities exclusively triggered by aggregation. In 
addition, it nicely recapitulates the migration route followed by the endogenous 
molecule. Thus, TMEM59 is exported to the plasma membrane and subsequently 
endocytosed to be finally degraded in lysosomes, just like the active chimeric constructs 
do if activated by aggregation. These two parallel routes suggest that TMEM59 could 
have an in situ LC3II-generating activity in any of these compartments, provided that a 
proper aggregating stimulus is present. The nature of such stimulus is currently 
unknown, although it certainly becomes available during SA infection. Since the 
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process described here involves LC3 labeling of non-autophagic vesicular 
compartments, it is reminiscent of the TLR2-mediated LC3 decoration of conventional 
phagosomes that has been previously described (Sanjuan et al., 2007). Stimulus-
dependent LC3 labeling of single membrane compartments might therefore constitute a 
general mechanism to promote a more efficient vesicle delivery to the lysosome, as it 
has been shown for LC3-positive phagosomes (Sanjuan et al., 2007). This notion is also 
suggested by our data showing autophagy-dependent degradation of the active CD16:7 
chimera (see Figure 4F). The need of an activating stimulus to promote LC3 labeling of 
these single membrane vesicles has perhaps precluded their previous identification as 
unconventional autophagic structures. 
ATG16L1 defines the site of LC3 lipidation by recruiting the LC3II synthesis 
complex (ATG12-ATG5) to defined membrane localizations (Harada et al., 2007; Fujita 
et al., 2008). Therefore, ATG16L1 constitutes a suitable target for selective autophagy 
against membranous compartments and, in fact, the existence of adaptor proteins that 
recruit ATG16L1 to specific sites has been anticipated (Fujita et al., 2008; Kageyama et 
al., 2011; Mizushima et al., 2011). We propose that TMEM59 may be one of these 
adaptors, and the ATG16L1-binding motif described here could facilitate identification 
of additional members of this group. Consistently, we found that the motif is conserved 
with the same ATG16L1-binding function in other molecules, confirming a wider 
representation. NODs are known to recruit ATG16L1 to the bacterial entry site, and 
therefore act as ATG16L1 adaptor molecules (Travassos et al., 2010). Intriguingly, we 
show that the N-terminal CARD of NOD2 binds ATG16L1 through the identified 
motif. However, NOD1 also binds ATG16L1 (Travassos et al., 2010) and its CARD 
lacks the motif, suggesting that other ATG16L1-binding sites probably exist in these 
molecules. Clathrin also interacts with ATG16L1 (Ravikumar et al., 2010), but its role 
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as an adaptor molecule for selective autophagy remains unexplored. Given the 
important roles that selective autophagy plays in multicellular organisms and the 
relevance that ATG16L1 seems to have in some of these directed processes, more 
molecules are expected to join the list of ATG16L1 adaptors in the near future. 
Our results show that the motif recognizes the C-terminal WD-repeat domain in 
ATG16L1, and therefore help answer the standing question of what the function of this 
region might be (Fujita et al., 2009; Mizushima et al., 2003). We propose that the WD 
repeats likely provide a docking platform for protein adaptors that engage ATG16L1. 
This interaction would leave the N-terminal part of the molecule free to interact with 
ATG5 (Mizushima et al., 2003) and form the functional complex that drives LC3 
lipidation. Since the ATG161-binding motif is present in proteins linked to native 
immunity (NOD2, TLR2 and TMEM59), our data are consistent the idea that the WD 
domain has evolved to fulfill more sophisticated autophagic functions that are exclusive 
of higher eukaryotes (Cadwell et al., 2009). Interestingly, the motif might have two 
overlapping functions in transmembrane proteins like TMEM59: intracellular 
trafficking and binding to ATG16L1. This coincidence of both signals in one aminoacid 
signature suggests a complex interaction between the two activities that might help 
integrate the final destination of the protein. 
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MATERIALS AND METHODS 
 
DNA constructs 
The source of all cDNAs and DNA manipulation methods are described in 
Supplementary Materials and Methods. Constructs expressing NOD2-CARD1-HA 
included aminoacids 1-122 of the whole molecule (Uniprot, Q9HC29), NOD1-CARD-
HA aminoacids 1-105 (Uniprot, Q9Y239), HA-TLR2-ID aminoacids 610-784 (Uniprot, 
O60603), ATG16L1-ΔWD aminoacids 1-319 (Uniprot, Q676U5) and ATG16L1-WD 
aminoacids 320-607. Point mutants were generated by site-directed mutagenesis 
(QuikChange, Stratagene). Mutant NOD2-CARD1-HA contains nine mutations to 
alanine in all residues potentially participating in an ATG16L1-binding motif (W63, 
E64, W68, E69, D70, Y71, E72, F74, and L77), since several aminoacid combinations 
can build different motif versions in the same region. HA-TLR2-ID, HA-T3JAM and 
HA-DEDD2 mutants were deleted versions lacking the motif (boxed regions in Figures 
8B and F).  
 
Immunofluorescence 
Cells were seeded onto poly-L-lysine-treated coverslips (Sigma). Coverslips were fixed 
(4% paraformaldehyde) and stained with the relevant antibodies (1 h, RT) as described 
(Klee and Pimentel-Muiños, 2005). To stain for endocytosed CD16:7 chimeras, 
unpermeabilized cells were quenched in vivo with unlabeled goat anti-mouse kappa 
chain (Jackson Immunoresearch, 40 min, 4ºC, 0,1% azide) to remove cell surface 
signal. Cells were fixed, permeabilized and stained with a goat anti-mouse kappa 
antibody conjugated to Cy3. Confocal pictures were taken using the 488-nm (Alexa-
488), 561-nm (Cy3) or 633-nm (Cy5) laser bands of a Leica SP5 confocal microscope. 
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Scale bars represent 10 μm in all micrographs. Quantifications were carried out using 
conventional microscopy. The number of GFP-LC3 dots per cell was evaluated on 
pictures taken with a Zeiss Axiophot-2 microscope equipped with a Hamamatsu 
ORCA-ER CCD camera and the Openlab software. To quantify transfected 293 cells 
showing GFP-LC3 activated by chimera aggregation, cells were centrifuged (cytospin) 
onto poly-L-lysine coated slides before fixation. 
 
Stimulation of CD16:7 chimeras  
Cells were transfected, split next day to as many wells as experimental points were to be 
used (control plus activation points) and stimulated 36 h post-transfection with the anti-
CD16 antibody (4 μg/ml, mAb, NA/LE formulation, BD) plus 10 μg/ml of a rabbit anti-
mouse polyclonal serum (Jackson Immunoresearch) for further aggregation. As all 
experimental points per construct derive from a single transfected well, control 
Western-blots can be carried out with unaggregated samples (the aggregating antibodies 
impaired protein detection in certain molecular weights). Aggregation was done for 16 
h in 293 cells, for 8 h in JAR cells (vesicle formation and colocalization with GFP-LC3 
were best detected at this latter time point) and for 4 h to evaluate colocalization with 
GFP-ATG16L1 or GFP-ATG5. ‘Control’ CD16:7 chimera refers to empty chimera. 
 
Bacteria infection assays 
HeLa cells were infected with GFP-expressing Staphylococcus aureus RN6390 (Kahl et 
al., 2000), kindly provided by Dr. A. Cheung (Dartmouth Medical School, New 
Hampshire, USA). Cells were incubated with the bacteria for 45 min, washed and 
treated with 100 μg/ml gentamicin (1 h) to inhibit extracellular proliferation of S. 
aureus. This was considered the 2 h infection time-point. Cells were washed and 
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incubated for additional time-points in the presence of 10 μg/ml gentamicin. 
Experiments involving siRNAs were done in HeLa cells expressing HA-LC3A. 
However, changes in LC3 lipidation were best detected in this setting using an anti-LC3 
antibody that does not recognize ectopic HA-LC3A, and therefore Western-blots 
display endogenous LC3 levels. Stainings for TMEM59-HA were done using an IgG1 
anti-HA mAb (Covance). This isotype has low affinity for protein A, thus minimizing 
direct binding to S. aureus (known to produce protein A; Sinha and Fraunholz, 2010). 
Preparations did not show detectable direct bacterial staining by immunofluorescence. 
For determination of CFUs, infected HeLa cells were lysed in 0,1% Triton X-100 and 
the lysates serially diluted for plating in BHI-agar and subsequent colony quantification. 
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FIGURE LEGENDS 
 
Figure 1. TMEM59 induces LC3 activation. (A) Clone P15 induces HA-LC3 lipidation. 
293T cells were transfected with P15 plus plasmids expressing HA-LC3A and/or the 
apoptotic inhibitor p35 (as shown), and lysed for Western-blotting against the indicated 
molecules (anti-HA for HA-LC3A). The figure shows that expression of P15 induces 
HA-LC3A conversion to a lower molecular weight form indicative of protein lipidation. 
This activity remains unchanged by p35. (B) P15 induces GFP-LC3 translocation to a 
vesiculated pattern. 293T cells were transfected with the indicated plasmids mixed with 
vectors expressing GFP-LC3A and p35. The known autophagic inducer bNIP3L 
constituted a positive control. Representative confocal pictures are shown. (C) 
TMEM59 induces HA-LC3 lipidation in different cell lines lacking the SV40 large T-
antigen plasmid amplification system. Cells were transfected with the shown plasmids 
and vectors expressing HA-LC3A (left) or HA-LC3B (right) and GST (as transfection 
control), and lysed for Western-blotting against the indicated molecules. (D) TMEM59 
induces GFP-LC3 activation. 293 cells were transfected with the indicated plasmids and 
GFP-LC3A (top) or GFP-LC3B (bottom). Representative confocal pictures are shown. 
(E) Quantification of the phenotype in D. The number of GFP-LC3-positive vesicles 
per transfected cell was scored for at least fifty cells. Data are expressed as means -/+ 
s.d. of one representative experiment of three repetitions. 
 
Figure 2. The intracellular domain (ID) of TMEM59 is necessary and sufficient for 
LC3 activation. (A) TMEM59 ID is required for HA-LC3 lipidation. 293 cells were 
transfected with full-length TMEM59 (FL) or a deleted version lacking the intracellular 
domain (ΔID, Δ263-281), HA-LC3A (left) or HA-LC3B (right) and GST. Cells were 
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lysed for Western-blotting against the shown molecules. (B) The ID is necessary for 
GFP-LC3 activation. 293 cells were transfected with the indicated TMEM59 constructs 
and GFP-LC3A or GFP-LC3B (as indicated). Representative confocal pictures are 
shown. (C) Quantification of the phenotype in B. Scoring and data expression were as 
in Figure 1E. (D) TMEM59 ID suffices for HA-LC3A lipidation. 293 cells were 
transfected with the indicated CD16:7 chimera (Control: empty chimera) and vectors 
encoding HA-LC3A and GST, subjected to aggregation with the shown amounts of 
anti-CD16 antibody and lysed for Western-blotting. The right panel shows control 
Western-blots demonstrating equal loading (ACTIN), transfection (GST) and chimera 
expression (CD16) in unaggregated samples, as all experimental points per chimera 
derive from a single transfection. (E) Comparable surface levels of CD16:7 constructs. 
Transfected 293 cells were processed for anti-CD16 flow cytometry. The graph displays 
percentages of positive cells (left axis) and means of fluorescence of positive cells (MF, 
right axis) obtained from triplicates. Data are expressed as means -/+ s.d. of the 
triplicates. (F) The ID suffices for HA-LC3B lipidation. (G) The ID suffices for GFP-
LC3 activation. 293 cells were transfected with the indicated chimeras and GFP-LC3A 
or GFP-LC3B, aggregated and mounted. Representative confocal pictures are shown. 
Activated GFP-LC3 appears as a collapsed mass of indiscernible vacuoles. (H) 
Quantification of the phenotype in G. As individual vesicles could not be counted, 
quantification was done as the percentage of transfected cells showing redistributed 
GFP-LC3. At least ten different fields were counted (about 400 cells). The experiment 
was repeated three times. Data are expressed as means -/+ s.d. of the triplicates. 
 
Figure 3. A minimal 19-aminoacid subdomain between aminoacids 263-281 holds the 
autophagic activity of TMEM59. (A, B) Ability of serial C-terminal deletions of 
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TMEM59 to activate LC3. 293 cells were transfected with the indicated TMEM59 C-
terminal deletions, HA-LC3A (A) or HA-LC3B (B) and GST, and lysed for Western-
blotting against the indicated molecules. (C) Aminoacids 263-281 retain the full 
potential of TMEM59 ID to promote HA-LC3 conversion. 293 cells were transfected 
with the shown CD16:7 chimeras, HA-LC3A or HA-LC3B (as indicated) and GST, and 
subjected to anti-CD16 aggregation before lysing them for Western-blotting. The lower 
panels show control Western-blots (unaggregated samples). (D) Aminoacids 263-281 
suffice for GFP-LC3 activation and retain the full potential of TMEM59 ID to promote 
GFP-LC3 activation. 293 cells were transfected with the indicated CD16:7 chimeras 
and GFP-LC3A or GFP-LC3B (as indicated), and subjected to anti-CD16 aggregation 
before fixing them for microscopy. The graph shows percentages of transfected cells 
exhibiting redistributed GFP-LC3. Quantification and data expression were done as in 
Figure 2H. (E) Aminoacids 282-323 of TMEM59 lack LC3-activation potential. 293 
cells were transfected with the shown chimeras, HA-LC3A or HA-LC3B and GST, and 
processed for Western-blotting against the indicated molecules. Control Western-blots 
of unaggregated samples are shown in the lower panels. (F) Surface expression levels of 
CD16:7 chimeras. Procedures and data expression were as in Figure 2E. The figure 
shows that the functional differences observed between CD16:7 chimeras (C-E) are not 
caused by differential surface expression. (G) Scheme of TMEM59 showing aminoacid 
positions and the minimal active subdomain (aminoacids 263-281). ED, extracellular 
domain; TM, transmembrane domain; ID, intracellular domain. 
 
Figure 4. The minimal active subdomain of TMEM59 promotes LC3 labeling and 
lysosomal degradation of its own vesicular compartment. (A) Endocytic vesicles 
containing aggregated CD16:7-263-281 become labeled with GFP-LC3. JAR cells were 
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transfected with vectors expressing the indicated CD16:7 chimeras and GFP-LC3A, and 
subjected to anti-CD16 aggregation for 8 h before staining for the endocytosed chimera 
(red). Representative confocal pictures are shown. The inset highlights a vesicle where 
the peripheral GFP-LC3 staining is particularly distinguishable. The right panel displays 
control Western-blots showing that chimera aggregation for 8 h activates HA-LC3A 
conversion in JAR cells. (B) Colocalization of endocytosed CD16:7-263-281 with 
EEA1 and CD63. JAR cells were transfected with CD16:7-263-281 and subjected to 
aggregation before staining them for the endocytosed chimera (red) and EEA1 or CD63 
(green; FITC-coupled primary antibodies), as indicated. Representative confocal 
pictures are shown. (C) Endocytosed CD16:7-263-281 localizes to LC3-labeled, single 
membrane vesicles. JAR cells were transfected with the CD16:7-263-281 chimera and a 
construct expressing human IgG1 fused to LC3A. Cells were subjected to anti-CD16 
aggregation for 8 h and processed for immunoelectron microscopy. Thick gold signal 
(18 nm): aggregated, endocytosed chimera; thin gold signal (12 nm): IgG1-LC3. 
Arrows indicate single membrane (black) or IgG1-LC3A (white). Scale bar: 400 nm. 
(D) Lysosomal inhibition increases HA-LC3II levels promoted by CD16:7-263-281. 
293 cells were transfected with the indicated chimera and HA-LC3A, and subjected to 
anti-CD16 aggregation in the absence or presence of bafilomycin (200 nM, added 4 h 
post-aggregation) before lysing them for Western-blotting against the indicated 
molecules. (E) Aggregation of CD16:7-263-281 promotes its own degradation. 293 
cells were transfected with the indicated constructs, aggregated and lysed for Western-
blotting. Shown are overexposed anti-CD16 Western-blots. (F) Degradation of CD16:7-
263-281 is inhibited by ATG5 depletion. 293 cells were transfected with the indicated 
siRNAs and subsequently with the shown CD16:7 constructs, aggregated and lysed for 
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anti-CD16 Western-blotting (left panel). The right panel displays control Western-blots 
showing ATG5 depletion. 
 
Figure 5. Alanine scanning approach to identify aminoacids in the active subdomain of 
TMEM59 that are essential for LC3 activation. (A) Identification of critical aminoacids 
for HA-LC3 conversion. 293 cells were transfected with the indicated CD16:7-263-281 
mutants and HA-LC3A, subjected to anti-CD16 aggregation and lysed for Western-
blotting against the indicated molecules. Asterisks mark mutations with reduced 
activity. Shown is one representative experiment of six repetitions. (B) Identification of 
critical aminoacids for GFP-LC3 activation and colocalization with the endocytosed 
chimera. JAR cells were transfected with the indicated CD16:7-263-281 mutants and 
GFP-LC3A, aggregated and stained for the endocytosed chimera (red). Preparations 
were scored by blindly counting the number of red vesicles (chimera) and green vesicles 
(GFP-LC3A) per cell, as well as the number of red vesicles colocalizing with green 
ones. The percentage of green vesicles colocalizing with red ones was close to 100% for 
all mutants, that is, virtually no GFP-LC3A vesicles were unrelated to endocytosed 
chimera (not shown). At least fifty cells were scored per experimental point. The 
experiment was repeated three times. The graph shows the number of GFP-LC3A 
vesicles per cell expressed as the percentage of the value obtained for the wild-type 
chimera (left axis), and the percentage of chimera vesicles labeled with GFP-LC3A 
(right axis). Data are expressed as means -/+ s.d. of the triplicates. Asterisks indicate 
significant differences with respect to wild-type values (paired Student’s t-test; P < 
0.01). (C) Representative confocal pictures of the phenotype produced by the indicated 
mutations. Procedures were as in B. (D) Simultaneous mutation of the four essential 
aminoacids to alanine blocks HA-LC3 conversion induced by CD16:7-263-281. 293 
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cells were transfected with the indicated chimeras (4M, quadruple mutant) and HA-
LC3A, aggregated and lysed for Western-blotting. (E) Simultaneous mutation of the 
four essential aminoacids blocks GFP-LC3 activation and colocalization with the 
endocytosed chimera. JAR cells were transfected with the indicated CD16:7-263-281 
constructs and GFP-LC3A, aggregated and stained for the endocytosed chimera (red). 
Representative confocal images are shown. (F) Quantification of the phenotype in E. 
Data gathering and expression were as in B. 
 
Figure 6. The minimal active subdomain of TMEM59 directly binds ATG16L1 through 
the identified functional motif. (A) Apposition events between GFP-ATG16L1 and 
endocytosed CD16:7-263-281. JAR cells were transfected with CD16:7-263-281 and 
GFP-ATG16L1 or GFP-BECLIN (as indicated), aggregated for 4 h and stained for the 
endocytosed chimera (red). Representative confocal pictures are shown. Two different 
examples are provided for GFP-ATG16L1. (B-D) 293T cells were transfected with the 
indicated constructs, lysed and subjected to GST immunoprecipitation (IP, 
immunoprecipitation; WB, Western-blot; TL, total lysate). Shown are Western-blots 
against the indicated molecules. (B) AU-ATG16L1 coprecipitates with wild-type (WT) 
TMEM59-GST but not with a mutated version where the four essential aminoacids 
were mutated to alanine (TMEM59-4M-GST). (C) Full-length TMEM59 and 
TMEM59-Δ282 coprecipitate with GST-ATG16L1, whereas the respective 4M versions 
do not. (D) AU-ATG16L1 coprecipitates with a fusion protein between GST and the 
minimal active peptide of TMEM59 (GST-263-281), but not with a 4M version (GST-
263-281-4M) or a GST fusion protein with the inactive portion of TMEM59-ID (GST-
282-323). (E) HA-ATG16L1 expressed in bacteria coprecipitates with a GST-263-281 
recombinant protein purified from bacterial cultures, but not with a 4M version of the 
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same construct or GST-282-323. The indicated GST partners were expressed in 
bacteria, purified and used for HA-ATG16L1 pull-down from crude bacterial lysates. 
Shown are Western-blots against the indicated molecules (PD, pull-down). A Coomasie 
staining of a protein gel with the purified GST fusion proteins is shown. The right panel 
compares the amount of HA-ATG16L1 pulled down by GST-263-281 with the signal 
provided by direct anti-HA immunoprecipitation. This result shows that about 20-25% 
of the available HA-ATG16L1 protein is precipitated by GST-263-281. Asterisks 
indicate irrelevant bands in B and D. 
 
Figure 7. The ATG16L1-binding motif present in TMEM59 recognizes the WD-repeat 
domain of ATG16L1. (A-F) 293T cells were transfected with the indicated constructs, 
lysed and subjected to GST immunoprecipitation. Shown are Western-blots against the 
indicated molecules. (A) A deleted version of ATG16L1 lacking the WD domain (HA-
ATG16L1-ΔWD) does not coprecipitate with TMEM59-GST. (B) TMEM59 does not 
coprecipitate with ATG16L1-ΔWD fused to GST. (C) The WD domain of ATG16L1 
(HA-ATG16L1-WD) suffices to coprecipitate with TMEM59-GST. (D) TMEM59 
coprecipitates with ATG16L1-WD fused to GST. (E) HA-ATG16L1-WD does not bind 
a 4M version of TMEM59-GST. (F) TMEM59-4M does not coprecipitate with the 
ATG16L1-WD fused to GST. 
 
Figure 8. The ATG16L1-binding motif is present with a similar ATG16L1-binding 
capacity in other molecules. (A) Alignment of the region that includes the motif in 
NOD2 with the same area in NOD1. The relevant aminoacid stretch is boxed. 
Individual aminoacid highlighting (black) in NOD2 indicates the residues identified by 
the Prosite algorithm as part of the motif. In NOD1, all residues that could be part of an 
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eventual motif are highlighted to indicate that they form an incomplete motif. (B) 
Aminoacid region in TLR2 that includes the motif. Highlighting indicates residues 
identified by Prosite as part of the motif. (C, D, E, G, H) 293T cells were transfected 
with the indicated constructs, lysed and subjected to GST immunoprecipitation. Shown 
are Western-blots against the indicated molecules. (C) The N-terminal CARD of NOD2 
(NOD2-CARD1-HA), but not the CARD of NOD1 (NOD1-CARD-HA), coprecipitates 
with GST-ATG16L1. (D) The intracellular domain of TLR2 (HA-TLR2-ID) 
coprecipitates with GST-ATG16L1. (E) Mutated versions (MUT) of NOD2-CARD1-
HA and HA-TLR2-ID (as shown) do not coprecipitate with GST-ATG16L1. (F) 
Aminoacid sequences of T3JAM and DEDD2 including the motif. Residues identified 
by the Prosite algorithm are highlighted. (G) Wild-type (WT) versions of HA-T3JAM 
and HA-DEDD2 (as indicated) coprecipitate with GST-ATG16L1. (H) Mutated 
versions (MUT) of HA-T3JAM and HA-DEDD2 do not coprecipitate with GST-
ATG16L1. Asterisks indicate irrelevant bands in C, D, and G. 
 
Figure 9. Endogenous TMEM59 mediates LC3 activation and interacts with ATG16L1 
in response to S. aureus (SA) infection. (A) Depletion of TMEM59 inhibits LC3II 
generation by SA at early infection times. HeLa cells were transfected with the 
indicated siRNAs and, 48 h later, infected with the bacteria (SA) for the shown times 
before lysing them for Western-blotting against the indicated molecules. The right panel 
shows successful TMEM59 depletion (rabbit anti-TMEM59 immunoprecipitation plus 
chicken anti-TMEM59 Western-blot). (B) Colocalization events between bacteria 
(GFP-labeled), TMEM59-HA and Cherry-LC3A in infected cells. HeLa cells stably 
expressing TMEM59-HA and Cherry-LC3A were infected for the indicated times (moi 
= 10), and processed for anti-HA immunofluorescence. Representative confocal images 
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are shown. The GFP, anti-HA (Cy5) and DAPI signals were pseudocolored in blue, 
green and white, respectively. Asterisks indicate overlay images: (*), Cherry-
LC3A/TMEM59; (**), Cherry-LC3A/TMEM59/bacteria; (***), Cherry-
LC3A/TMEM59/bacteria/DAPI. (C) Colocalization between bacteria, TMEM59-HA 
and Cherry-ATG16L1. HeLa cells stably expressing TMEM59-HA and Cherry-
ATG16L1 were infected with SA (2 h, moi = 10), and processed for anti-HA 
immunofluorescence. Representative confocal pictures are shown. Asterisks indicate 
overlays as in B. (D) SA promotes coprecipitation of endogenous ATG16L1 with 
endogenous TMEM59. HeLa cells were infected with SA (2 h, moi = 10), lysed and 
subjected to immunoprecipitation with anti-TMEM59 antibodies or irrelevant protein G 
beads (as indicated). Immunoprecipitates were processed for Western-blotting. The 
right panel shows control Western-blots of the lysates used for immunoprecipitation. 
(E) Depletion of TMEM59 reduces recovery of SA from infected cells. HeLa cells were 
transfected with the indicated siRNAs, infected with SA 96 h later (5 h, moi = 0,1) and 
lysed for CFU evaluation. The experiment was carried out three independent times. The 
graph displays average CFU counts obtained for the 10-1 dilution of the relevant 
extracts, -/+ s.d. of the three data sets. Asterisks indicate significant differences (P < 
0.01, paired Student’s t-test). The right panel shows successful TMEM59 depletion 
(anti-TMEM59 immunoprecipitation plus anti-TMEM59 Western-blot). 
 









